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Abstract
Previous studies have shown that adrenomedullin (AM), a potent vasodilatory peptide, is upregulated during sepsis.
However, it remains unknown whether the increased AM observed under such conditions is solely due to the elevated levels
of circulating lipopolysaccharide (LPS). To determine this, an Alzet micro-osmotic pump, containing a low dose of
Escherichia coli LPS or vehicle (sterile normal saline), was implanted in the peritoneal cavity of the normal male adult rat. At
10 h after the pump implantation, samples of blood and small intestine were harvested for the determination of AM by
radioimmunoassay. In additional groups, rats were subjected to polymicrobial sepsis by cecal ligation and puncture (CLP).
LPS binding agent polymyxin B was administrated intramuscularly at 1 h prior to as well as 5 h after the onset of sepsis. At
10 h after CLP or sham-operation, blood and intestinal samples were harvested and levels of AM were then determined.
Plasma levels of LPS were also measured by Limulus amebocyte lysate assay. The results indicate that administration of a low
dose of LPS via the peritoneal cavity in normal animals (which did not significantly alter cardiac output, blood pressure or
heart rate) markedly increased plasma and intestinal levels of AM. In addition, plasma and tissue levels of AM increased
significantly at 10 h after CLP. Administration of polymyxin B, however, attenuated the increase in AM levels under such
conditions. Similarly, the increased plasma levels of LPS was significantly reduced by polymyxin B during sepsis. These
results, taken together, suggest that the upregulated AM observed during polymicrobial sepsis is at least in part due to the
increase in circulating levels of endotoxin. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Human adrenomedullin (AM), a 52-amino-acid
residue peptide with potent vasodilatory properties,
was ¢rst isolated and reported by Kitamura et al.
from human pheochromocytomas and reported in
1993 [1]. AM has a six-residue structure formed by
an intramolecular disul¢de bridge and a carboxy-ter-
minal amidated residue. The complementary DNAs
encoding human and rat AM have been cloned and
sequenced [2,3]. Rat AM has 50 amino acid residues,
with two amino acid deletions and six substitutions
compared with human AM [3]. AM transcripts and
proteins are expressed in a large number of tissues
and cell populations [2^6]. Although its actions are
associated with cardiovascular, endocrine, and renal
mechanisms that control £uid and electrolyte homeo-
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stasis [7], the vasodilatory properties of AM are of
particular interest in the pathophysiology of sepsis.
In this regard, studies have indicated that AM is
upregulated during sepsis [8^10], as well as under
other pathophysiologic conditions such as systemic
in£ammatory response syndrome [11], endotoxic
shock [12], and acute myocardial infarction [13]. De-
spite the fact that several vasoactive mediators such
as nitric oxide, prostacyclin, and calcitonin gene-re-
lated peptide have been implicated in the progressive
change in cardiovascular responses during sepsis, re-
cent studies have suggested that the increased AM
plays an important role in initiating the hyperdynam-
ic response during the early stage of sepsis [14,15].
Moreover, the reduced vascular responsiveness to
AM appears to be responsible for producing the
transition from the early hyperdynamic phase to
the late, hypodynamic phase of sepsis [16,17].
Although both AM and endotoxin are increased dur-
ing polymicrobial sepsis [9,18], it remains unknown
whether the increased levels of AM observed under
such conditions are solely due to the elevated levels
of circulating lipopolysaccharide (LPS). Therefore,
our hypothesis is that the increase in circulating
LPS plays a major role in stimulating AM produc-
tion during polymicrobial sepsis. To test this hypoth-
esis, experiments were conducted to determine
whether administration of a low dose of LPS (which
does not signi¢cantly alter hemodynamics) increases
plasma and intestinal levels of AM in normal ani-
mals. Moreover, the e¡ects of the LPS binding agent
polymyxin B (PMB) on AM production were also
examined in septic animals.
2. Materials and methods
2.1. Experimental animals
Male adult Sprague^Dawley rats (275^325 g) were
purchased from Charles River Laboratories (Wil-
mington, MA) and used in this study. All surgical
procedures were performed using aseptic procedures
with the exception of the animal model of sepsis
induced by cecal ligation and puncture (CLP). The
experiments described below were performed in ad-
herence to the NIH Guidelines for the Use of Exper-
imental Animals. This project was approved by the
Institutional Animal Care and Use Committee of the
University of Alabama at Birmingham.
2.2. Intraperitoneal administration of a low dose of
LPS in normal animals
Rats were fasted overnight but allowed water ad
libitum prior to the experiment. The animals were
then anesthetized with iso£urane inhalation and a
2-cm midline incision was performed. An Alzet mi-
cro-osmotic pump (200 Wl) containing 0.375 Wg
Escherichia coli LPS (055:B5, Difco) or vehicle (ster-
ile normal saline) was implanted in the abdominal
cavity followed by closure of the abdominal wall in
layers. All rats received normal saline (3 ml/100 g
body wt.) subcutaneously immediately after the
pump implantation to provide £uids since the ani-
mals were subsequently fasted for another 10 h.
The infusion rate of the pump was set at 8 Wl/h for
a duration of 10 h. Each rat received approximately
0.5 Wg/kg body wt. endotoxin, similar to that admin-
istered to the normal mouse for 10 h by Ayala et al.
[19]. Plasma levels of AM and LPS as well as intes-
tinal levels of AM were then determined at the con-
clusion of LPS administration.
2.3. Animal model of polymicrobial sepsis and
administration of PMB
Polymicrobial sepsis was induced by CLP as pre-
viously described [20,21]. In brief, male adult rats
were fasted overnight but allowed water ad libitum
prior to the experiment. The animals were then anes-
thetized with iso£urane, and a 2-cm midline incision
was performed. The cecum was exposed, ligated just
distally to the ileocecal valve to avoid intestinal ob-
struction, and then punctured twice with an 18-gauge
needle. The cecum was squeezed to expel a small
amount of fecal material and the abdominal incision
was closed in two layers. Sham-operated rats under-
went the same surgical procedure except that the
cecum was neither ligated nor punctured. All animals
received normal saline (3 ml/100 g body wt.) subcu-
taneously immediately after the operation to provide
£uid resuscitation. At 1 h before CLP as well as at
5 h after CLP, PMB (Sigma, St. Louis, MO) at a
dose of 600 U/kg body wt. [22] or 0.5 ml normal
saline was administered intramuscularly. PMB is a
BBADIS 62055 6-9-01
S. Yang et al. / Biochimica et Biophysica Acta 1537 (2001) 167^174168
LPS binding antibiotic which binds and detoxi¢es
lipid A [23]. In vitro studies have con¢rmed that
PMB neutralizes E. coli LPS activity [24]. At 10 h
after the onset of sepsis, plasma levels of AM and
LPS and intestinal levels of AM were determined as
described below.
2.4. Determination of plasma and intestinal levels of
AM
At 10 h after intraperitoneal infusion of the
low dose LPS or 10 h after CLP, blood samples
(V1.5 ml each) and small intestine (middle jejunum;
V0.5 g) were harvested under iso£urane anesthesia.
A radioimmunoassay kit speci¢c for rat AM (Penin-
sula Laboratories, Belmont, CA) was used for AM
measurement according to the procedure provided by
the manufacturer as described in detail by us [9,10].
Brie£y, blood samples were collected into a polypro-
pylene tube containing EDTA (1 mg/ml) and aproti-
nin (500 KIU/ml) and plasma was separated imme-
diately. For intestinal AM measurement, V0.5 g
tissue was homogenized with 2 ml Tris^HCl
(50 mM, pH 7.4). After centrifugation at 16 000Ug
for 10 min, the supernatant was collected and stored
at 380‡C until assayed. AM was extracted from
0.5 ml plasma or supernatant on C18 columns eluted
with 60% acetonitrile in 1% tri£uoroacetic acid. Elu-
ates were evaporated to dryness using a centrifugal
concentrator. Samples were dissolved in RIA bu¡er.
Samples were then incubated overnight at 4‡C with
the antibody raised against rat AM. [125I]AM was
then added for further overnight incubation. Free
and bound fractions of [125I]AM were separated by
the addition of a secondary antibody and centrifuga-
tion. Radioactivity of the pellet was then measured.
The rat AM assay does not have any cross-reactivity
with human AM, amykin, or endothelin-1 [15].
2.5. Determination of plasma levels of LPS
At 10 h after the infusion of LPS or 10 h after
CLP, V1-ml blood samples were collected into a
sterile glass tube and plasma was separated immedi-
ately. Plasma samples were then transferred to sterile
polystyrene tubes and stored at 380‡C until assayed.
LPS levels in the plasma were measured using a
Limulus amebocyte lysate (LAL) kit (Associates of
Cape Cod, Falmouth, MA) according to the manu-
facturer’s instruction. Brie£y, 50 Wl plasma samples
were diluted 1:10 in LAL reagent solution. Endotox-
in (E. coli 0113:H10, provided by the manufacturer)
was used as the standard. Both standard and samples
were heated for 15 min at 75‡C and were then added
to a 96-well plate. Fifty Wl pyrochrome was added to
each well, mixed on a plate shaker for 30 s, and
incubated for 35 min at 37‡C followed by the addi-
tion of 25 Wl 50% acetic acid to stop the reaction.
The optical density was determined at 405 nm using
a spectrophotometer. The levels of endotoxin were
then calculated and expressed as EU/ml.
2.6. Determination of cardiac output (CO), mean
arterial blood pressure (MAP), and heart rate
In additional groups of animals, the right femoral
artery was cannulated with a PE-50 catheter which
was connected with a blood pressure analyzer (Digi-
Med, Louisville, KY) to monitor MAP and heart
rate at 10 h after intraperitoneal administration of
the low dose of LPS. CO was determined using a
dye dilution technique as previously described [25].
Fig. 1. Alterations in plasma (A) and intestinal levels (B) of
AM after peritoneal implantation of a 200-Wl Alzet micro-os-
motic pump containing 0.375 Wg E. coli LPS or vehicle (sterile
normal saline) at a rate of 8 Wl/h for 10 h. Data are expressed
as mean þ S.E. (n = 6/group), and compared by Student’s t-test:
*P6 0.05 vs. vehicle-infused animals.
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2.7. Statistical analysis
Data are presented as mean þ S.E. Student’s t-test
was employed for comparison between two groups.
One-way analysis of variance (ANOVA) and Tukey’s
test were employed for comparison among di¡erent
groups of animals. The di¡erences were considered
signi¢cant at P90.05.
3. Results
3.1. Alterations in plasma and intestinal levels of AM
after intraperitoneal administration of LPS
As indicated in Fig. 1A,B, plasma and intestinal
levels of AM increased by 155% (P6 0.05) and 35%
(P6 0.05), respectively, after intraperitoneal admin-
istration of the low dose of LPS for 10 h as com-
pared to vehicle-infused animals. Plasma levels of
LPS increased from 0.28 þ 0.13 EU/ml to
2.27 þ 0.37 EU/ml (by 711%; P6 0.05) at 10 h after
the implantation of the micro-osmotic pump contain-
ing low dose of endotoxin (Fig. 2). The change in
plasma and intestinal levels of AM after intraperito-
neal administration of LPS does not appear to be
due to LPS-induced alterations in hemodynamics
since CO, MAP, and heart rate did not alter signi¢-
cantly after intraperitoneal administration of LPS
(Table 1).
3.2. E¡ects of PMB on AM and LPS levels during
sepsis
As shown in Fig. 3A, plasma levels of AM in-
Fig. 3. Alterations in plasma (A) and intestinal levels (B) of
AM at 10 h after CLP or sham operation following administra-
tion of PMB at 1 h prior to CLP and 5 h after CLP at a dose
of 600 U/kg body wt. or vehicle (sterile normal saline). Data
are expressed as mean þ S.E. (n = 6/group), and compared by
one-way ANOVA and Tukey’s test: *P6 0.05 vs. respective
sham group; #P6 0.05 vs. CLP.
Fig. 2. Alterations in plasma levels of LPS after peritoneal im-
plantation of a 200-Wl Alzet micro-osmotic pump containing
0.375 Wg E. coli LPS or vehicle (sterile normal saline) at a rate
of 8 Wl/h for 10 h. Data are expressed as mean þ S.E. (n = 6/
group), and compared by Student’s t-test : *P6 0.05 vs. vehicle-
infused animals.
Table 1
Alterations in cardiac output (CO), mean arterial pressure (MAP) and heart rate after 10-h intraperitoneal infusion of a low dose of
LPS
CO (ml/min/100 g body wt.) MAP (mmHg) Heart rate (beats/min)
Vehicle 35.8 þ 5.6 109 þ 2 359 þ 4
LPS 36.8 þ 2.2 109 þ 3 377 þ 11
LPS or vehicle was administered intraperitoneally using 200-Wl Alzet osmotic pumps at a rate of 8 Wl/h for 10 h. Data are presented
as mean þ S.E. (n = 4). Student’s t-test indicates that there was no signi¢cant di¡erence in the measured parameters between LPS- and
vehicle-infused animals.
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creased by 463% at 10 h after CLP (P6 0.05). Intra-
muscular administration of PMB, however, reduced
the levels of AM by 54% (P6 0.05) despite the fact
that plasma levels of AM in PMB-treated septic ani-
mals remained signi¢cantly higher than the respective
shams. Similarly, intestinal levels of AM increased by
460% at 10 h after CLP (P6 0.05) and intramuscular
administration of PMB attenuated AM levels by 39%
(P6 0.05, Fig. 3B). It should be noted that admin-
istration of PMB in sham-operated animals did not
signi¢cantly alter plasma and intestinal levels of AM
(Fig. 3A,B). Plasma levels of LPS increased from
0.41 þ 0.15 EU/ml to 3.54 þ 0.15 EU/ml at 10 h after
the onset of sepsis (P6 0.05; Fig. 4). Although ad-
ministration of PMB attenuated the increase of LPS
by 49% (P6 0.05), it did not completely prevent the
increase of plasma LPS at 10 h after CLP (Fig. 4).
4. Discussion
The potent vasodilatory peptide AM produces var-
ious e¡ects on systemic and local hemodynamics.
Studies by Parkes have indicated that administration
of AM in conscious sheep decreases blood pressure
and increases heart rate, which is associated with an
increase in cardiac output and coronary blood £ow
and decrease in peripheral vascular resistance [26].
Similarly, administration of AM in the rat increases
cardiac output and regional blood £ow in the heart,
lungs, kidneys, and small intestine [27]. AM elicits its
vasodilatory e¡ects through two di¡erent mecha-
nisms: a direct e¡ect on vascular smooth muscle cells
to increase intracellular cAMP by stimulating AM
receptors [calcitonin receptor-like receptor (CRLR),
receptor activity modifying protein-2 or -3 (RAMP-
2, RAMP-3)] and adenylate cyclase, and an indirect
e¡ect on vascular endothelial cells by increasing en-
dothelium-derived nitric oxide release [28]. More-
over, we have recently demonstrated that administra-
tion of synthetic rat AM at a dose similar to that
observed during early sepsis (which does not produce
any signi¢cant alterations in blood pressure or heart
rate) markedly increases cardiac output, stroke vol-
ume, and tissue perfusion while decreasing total vas-
cular resistance [15]. Thus, the upregulated AM ob-
served early after the onset of sepsis plays an
important role in producing the hyperdynamic re-
sponse during the early stage of polymicrobial sepsis
[9,16]. The reduction in vascular responsiveness to
AM appears to be responsible for the transition
from the hyperdynamic phase to the hypodynamic
phase of sepsis [16,17]. Thus, investigation of this
potent vasodilatory peptide is of great interest in
the biopathology of sepsis.
It has been reported that upregulation of AM can
be observed following administration of endotoxin
under in vivo as well as in vitro conditions [29,30].
When endotoxin is infused at a dose of milligrams
per kilogram of body weight, it produces a shock-like
state similar to that seen in septic shock [31]. In this
regard, Shoji et al. reported that intravenous
injection of LPS at a dose of 5 mg/kg into the rat
increased plasma AM concentration by nearly
20-fold, and caused mortality after 3 h of LPS injec-
tion [32]. Alternatively, endotoxin has been adminis-
trated in a chronic low dose manner (9 1 Wg/kg body
wt.), which induces a hyperdynamic state comparable
to that seen in early sepsis [33,34]. It has been re-
ported that plasma AM concentration increased in a
dose-dependent manner up to 5 mg/kg of LPS [32].
In addition, intravenous injection of LPS (5 mg/kg)
augmented AM gene transcription in the aorta, car-
diac atrium, cardiac ventricle, lungs, adrenal gland,
kidneys, skeleton muscle, brain, thymus, testis, sub-
maxillary gland, liver, spleen, stomach, jejunum, and
ileum [32]. In LPS-treated animals, high levels of AM
mRNA were observed in lung, thoracic aorta and
adrenal gland, but its increment ratio was highest
Fig. 4. Alterations in plasma levels of LPS at 10 h after CLP
or sham operation following administration of PMB, at 1 h pri-
or to CLP and at 5 h after CLP at a dose of 600 U/kg body
wt. or vehicle (sterile normal saline). Data are expressed as
mean þ S.E. (n = 6/group), and compared by one-way ANOVA
and Tukey’s test : *P6 0.05 vs. respective sham group;
#P6 0.05 vs. CLP.
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in ileum/jejunum followed by liver, lung and aorta
[32].
The results indicate that administration of the low
dose of LPS increased plasma and intestinal levels of
AM. Since intraperitoneal administration of the low
dose of LPS did not alter cardiac output and blood
pressure, it is unlikely that the increased production
of AM under such conditions was secondary to
changes in hemodynamics. The role of LPS in stim-
ulating AM production was further con¢rmed by
administration of PMB, in which PMB signi¢cantly
reduced the increase in plasma and intestinal levels of
AM at 10 h after CLP. These results, taken together,
suggest that the increased production of AM during
sepsis is at least in part due to LPS stimulation. PMB
is an antibiotic used to treat Gram-negative infec-
tions. It binds and detoxi¢es lipid A, which is one
of the three distinct regions of LPS [23]. Studies have
shown that low doses of PMB signi¢cantly decreased
endotoxin levels in septic animals or following endo-
toxemia [22,35]. A low dose of PMB (600 U/kg) was
found to signi¢cantly improve survival of septic rats
and attenuate nitric oxide and tumor necrosis factor
(TNF)-K production from Kup¡er cells [22]. More-
over, studies indicated that pretreatment with PMB
protects rabbits against shock induced by E. coli LPS
[24]. The results in the present study also indicate
that intramuscular injection of the low dose of
PMB in septic animals decreased plasma levels of
LPS, which resulted in attenuated levels of plasma
and intestinal levels of AM at 10 h after the onset of
sepsis. It should be noted that while intraperitoneal
administration of LPS increased plasma and intesti-
nal levels of AM, the magnitude of the increase is
approximately 50% of those observed at 10 h after
the onset of sepsis. This could be due to the fact that
LPS levels in septic animals were 56% higher than in
LPS-infused animals. Although the dosage of PMB
used in this study (600 U/kg) has been shown to
improve the survival rate of septic animals [22], it
does not appear that 600 U/kg is the optimal dosage
since plasma levels of LPS decreased only by 49%
(Fig. 4). Similarly, intestinal and plasma levels of
AM only decreased by 39^54%. Despite the fact
that a dose^response curve of PMB was not con-
ducted, the ¢ndings that partial inhibition of LPS
during sepsis reduced AM production strongly sug-
gest the important role of LPS in stimulating AM
production under such conditions. Nonetheless, it
remains unknown whether a high dosage of PMB
prevents the increase of LPS and AM during poly-
microbial sepsis.
LPS, a main component of bacterial endotoxin, is
known to upregulate proin£ammatory cytokines
such as TNF-K and interleukin (IL)-1L [36,37]. LPS
and those in£ammatory cytokines are found to co-
operatively augment gene transcription of AM, re-
sulting in a marked elevation in AM production.
Studies by Sugo et al. have shown that IL-1K and
L as well as TNF-K and -L markedly augmented
production and gene expression of AM [29]. Studies
by Isumi et al. indicated that TNF and IL-1 as well
as LPS augmented AM secretion from endothelial
cells [38]. Although it remains to be determined
whether the upregulatory e¡ect of LPS on AM pro-
duction is mediated by proin£ammatory cytokines, it
is likely that LPS and cytokines synergistically en-
hance AM production during sepsis. A recent study
by Elsasser et al. has demonstrated that underlying
disease conditions such as a chronic subclinical para-
sitic infection augments plasma and tissue AM re-
sponses [39]. In addition, glucocorticoid appears to
be required for the increased AM secretion following
the administration of endotoxin [40]. Thus, factors
other than proin£ammatory cytokines appear to be
also involved in AM production during sepsis.
Studies have shown that experimental sepsis is as-
sociated with a hyperdynamic phase in the early
stage of sepsis which happens at 2^10 h after cecal
ligation and puncture (characterized by increased
cardiac output, organ blood £ow, oxygen delivery,
and decreased vascular resistance) followed by a hy-
podynamic phase at 16 h and late after CLP (char-
acterized by decreased cardiac output, organ blood
£ow, oxygen delivery, and increased vascular resis-
tance) [21]. We have demonstrated that circulating
levels of AM increase signi¢cantly during both early
and late stages of sepsis [9]. Studies have also shown
that the upregulated AM observed early after the
onset of sepsis plays an important role in producing
the hyperdynamic response [15]. Moreover, the tran-
sition from the hyperdynamic phase to the hypody-
namic phase appears to be due to the reduction of
vascular responsiveness to AM during the progres-
sion of polymicrobial sepsis [17]. Our recent studies
suggest that the gut is the major source of AM re-
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lease during sepsis as evidenced by higher levels of
AM in the portal than in systemic blood, increased
intestinal levels of AM, and increased immunohisto-
chemical stainings in the mucosa, submucosa, and
nerve ¢bers of the gut during sepsis [41]. The results
from the present study further con¢rm that intestinal
levels of AM increased signi¢cantly following the
onset of sepsis. In addition, AM immunostainings
increase in cardiovascular tissues (mainly in vascular
endothelial cells and cardiac myocytes) during sepsis
[10]. It has been suggested that blood vessels may be
a source of plasma AM [10,42]. Studies have also
indicated vascular smooth muscle cells as well as
endothelial cells are also responsible for producing
and secreting AM during stimulation by LPS
[30,32]. AM gene transcription in nonvascular cells
of the lungs, intestines and some other tissues are
also augmented by LPS stimulation [43]. Although
the gut appears to be the primary source of AM
production during sepsis, other tissues or cell popu-
lation are also likely to play a critical role in LPS-
induced AM synthesis and release under such condi-
tions.
In summary, our results indicate that intraperito-
neal administration of a low dose of LPS for 10 h
increased plasma LPS, which resulted in a signi¢cant
increase in plasma and intestinal levels of AM. Sim-
ilarly, plasma levels of LPS increased at 10 h after
the onset of sepsis, which was associated with an
increase of plasma and intestinal levels of AM. Ad-
ministration of the LPS-binding agent PMB, how-
ever, attenuated the increase in plasma and intestinal
levels of AM, which appears to be due to the reduced
LPS levels by PMB during sepsis. These results, tak-
en together, suggest that LPS plays an important role
in stimulating AM production/secretion during poly-
microbial sepsis.
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